These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19367236)

  • 1. Lipoproteins, inflammatory biomarkers, and cardiovascular imaging in the assessment of atherosclerotic disease activity.
    Vanhecke TE; Franklin BA; Maciejko J; Chinnaiyan K; McCullough PA
    Rev Cardiovasc Med; 2009; 10(1):51-8. PubMed ID: 19367236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
    Naghavi M; Falk E; Hecht HS; Jamieson MJ; Kaul S; Berman D; Fayad Z; Budoff MJ; Rumberger J; Naqvi TZ; Shaw LJ; Faergeman O; Cohn J; Bahr R; Koenig W; Demirovic J; Arking D; Herrera VL; Badimon J; Goldstein JA; Rudy Y; Airaksinen J; Schwartz RS; Riley WA; Mendes RA; Douglas P; Shah PK;
    Am J Cardiol; 2006 Jul; 98(2A):2H-15H. PubMed ID: 16843744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory markers: linking unstable plaques to coronary event, an interventional perspective.
    Aronson D
    Int J Cardiovasc Intervent; 2004; 6(3-4):110-8. PubMed ID: 16146903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arithmetic of vulnerable plaques for noninvasive imaging.
    Narula J; Garg P; Achenbach S; Motoyama S; Virmani R; Strauss HW
    Nat Clin Pract Cardiovasc Med; 2008 Aug; 5 Suppl 2():S2-10. PubMed ID: 18641603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
    Naghavi M; Libby P; Falk E; Casscells SW; Litovsky S; Rumberger J; Badimon JJ; Stefanadis C; Moreno P; Pasterkamp G; Fayad Z; Stone PH; Waxman S; Raggi P; Madjid M; Zarrabi A; Burke A; Yuan C; Fitzgerald PJ; Siscovick DS; de Korte CL; Aikawa M; Airaksinen KE; Assmann G; Becker CR; Chesebro JH; Farb A; Galis ZS; Jackson C; Jang IK; Koenig W; Lodder RA; March K; Demirovic J; Navab M; Priori SG; Rekhter MD; Bahr R; Grundy SM; Mehran R; Colombo A; Boerwinkle E; Ballantyne C; Insull W; Schwartz RS; Vogel R; Serruys PW; Hansson GK; Faxon DP; Kaul S; Drexler H; Greenland P; Muller JE; Virmani R; Ridker PM; Zipes DP; Shah PK; Willerson JT
    Circulation; 2003 Oct; 108(15):1772-8. PubMed ID: 14557340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic significance of coronary calcification in asymptomatic persons].
    Möhlenkamp S; Erbel R
    MMW Fortschr Med; 2007 Apr; 149(14):38-40. PubMed ID: 17668761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical disease detection: advanced imaging applications.
    Flice R; Lima JA; Bluemke DA
    Top Magn Reson Imaging; 2007 Oct; 18(5):339-48. PubMed ID: 18025988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
    Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
    Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a preventive value in non-invasive cardiac imaging? Debate on the case of a marathon runner.
    Plicht B; Erbel R; Möhlenkamp S
    Dtsch Med Wochenschr; 2009 Oct; 134(40):e1-5, 1990-4. PubMed ID: 19777410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factor management: antiatherogenic therapies.
    Gielen S; Sandri M; Schuler G; Teupser D
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S29-36. PubMed ID: 19675434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary-calcium screening to improve risk stratification in primary prevention.
    Raggi P
    J La State Med Soc; 2002; 154(6):314-8. PubMed ID: 12517028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise and acute cardiovascular events: placing the risks into perspective.
    ;
    Med Sci Sports Exerc; 2007 May; 39(5):886-97. PubMed ID: 17468590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation between Framingham risk categories and the presence of functionally relevant coronary lesions as determined on multislice computed tomography and stress testing.
    Nucifora G; Schuijf JD; van Werkhoven JM; Djaberi R; van der Wall EE; de Roos A; Scholte AJ; Schalij MJ; Jukema JW; Bax JJ
    Am J Cardiol; 2009 Sep; 104(6):758-63. PubMed ID: 19733707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease.
    Tsimikas S
    Am J Cardiol; 2006 Dec; 98(11A):9P-17P. PubMed ID: 17126679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokines and cardiovascular risk.
    Aukrust P; Halvorsen B; Yndestad A; Ueland T; Øie E; Otterdal K; Gullestad L; Damås JK
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1909-19. PubMed ID: 18669888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inflammatory and anti-inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting?].
    García-Moll X
    Rev Esp Cardiol; 2005 Jun; 58(6):615-7. PubMed ID: 15970115
    [No Abstract]   [Full Text] [Related]  

  • 19. The vulnerable patient: refocusing on the plaque?
    Eijgelaar WJ; Heeneman S; Daemen MJ
    Thromb Haemost; 2009 Aug; 102(2):231-9. PubMed ID: 19652873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory biomarkers of coronary atheromatous plaque vulnerability.
    Avanzas P; Arroyo-Espliguero R; Garcia-Moll X; Kaski JC
    Panminerva Med; 2005 Jun; 47(2):81-91. PubMed ID: 16210993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.